Compare Amgen, Inc. (AMGN) vs British American Tobacco PLC (BTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs British American Tobacco PLC — how do they compare? Amgen, Inc. trades at $417.84 (market cap $225.15B), while British American Tobacco PLC trades at $57.34 (market cap $120.84B). The key difference: Amgen, Inc. is the larger of the two by market cap, and British American Tobacco PLC pays the higher dividend (5.98%). Which is the better fit depends on your goals.
| AMGN | BTI | |
|---|---|---|
Market Cap | $225.15B | $120.84B |
Sector | Health | Consumer Staples |
52-Week High | $417.20 | $66.70 |
52-Week Low | $271.18 | $50.39 |
Enterprise Value | $268.47B | $164.79B |
Dividend Yield | 2.42% | 5.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.84, up 0.85% today, near its R1 resistance of $418. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, and revenue exceeding $10 billion. Analyst consensus is bullish with 23 Buy ratings, a $392.53 price target, and technical indicators signaling a bullish trend from moving averages, though RSI levels suggest overbought conditions.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high debt levels and competitive pressures. The stock offers a dividend yield supported by consistent payouts, with investor sentiment bolstered by recent earnings outperformance and media coverage highlighting growth prospects.
British American Tobacco (BTI) trades at $57.35, up 0.95% with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 24.99% net income margin and 13.33% ROE, supported by $25.6B revenue. Recent restructuring including 5,500 job cuts aims to streamline operations while maintaining dividend payments of $0.83 per share. Cash flow trends show operational strength despite recent net cash outflow of -$1.1B in 2025.
BTI presents a mixed outlook with attractive valuation (P/E 14.21) and 66.7% analyst buy rating, but faces regulatory headwinds and declining combustible sales. The transition to next-generation products like Velo nicotine pouches shows promise, though execution risks remain. The stock offers income appeal with consistent dividends but requires monitoring of debt levels and market share trends in non-combustible segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →
